Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients

Burns, Jane L.; Saiman, Lisa; Whittier, Susan; Krzewinski, Jay; Liu, Zhenling; Larone, Davise H.; Marshall, Steven A.; Jones, Ronald N.

doi:10.1016/s0732-8893(01)00234-6

Cited by 77 publications

(68 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In another study investigating the P. aeruginosa isolates from 597 cystic fibrosis patients in the USA, it was reported that the E-test method was compatible with both mucoid and non-mucoid P. aeruginosa isolates when compared with the reference broth microdilution method whereas disk diffusion method was less compatible with mucoid isolates [21].…”

Section: Discussionmentioning

confidence: 99%

Determination of Piperacillin/Tazobactam and Ticarcillin/Clavulanate Susceptibilities in Pseudomonas aeruginosa Isolates in Hospitalised Patients by E-test Gradient Method and Comparison of Results with Disk Diffusion Tests

Direkel¹,

Uzunoğlu²,

Uzalp³

et al. 2017

Clin Microbiol

View full text Add to dashboard Cite

Pseudomonas aeruginosa is an important opportunistic pathogen in human infections. P. aeruginosa is naturally resistant to many antibiotics and mutations can result in resistance development during treatment as well. Piperacillin/tazobactam and Ticarcillin/clavulanate are β-lactam/β-lactamase inhibitor combination with a wide spectrum of antibacterial activity. In this study was aimed to determine the susceptibility of P. aeruginosa isolates to Piperacillin/tazobactam and Ticarcillin/clavulanate antibiotics by Epsilometer test in the patients in intensive care units of Giresun State Hospital and to compare PIP/TZP results by Disk Diffusion method. Sensitivities of PIP/TZP were determined via Kirby Bauer disk diffusion method and MIC values of the isolates against PIP/TZP and TIC/CLA were determined by E-test. By using E-test method and in accordance with the CLSI standards, 43 (64%) isolates were found to be susceptible and 24 (36%) isolates were found to be resistant to TIC/CLA. For the PIP/TZP, 49 of the 67 isolates were susceptible, three were intermediate and 15 were resistant by using disk diffusion method. On the other hand, according to the E-test results, 63 isolates were susceptible and four isolates were resistant. When compared to eleven isolate E-test methods, the disk diffusion method was incorrectly determined to be resistant. The results of our study suggest that it would be more appropriate to use E-test method to confirm the results of the isolates which were found to be resistant against PIP/TZP by disk diffusion method.

show abstract

Section: Discussionmentioning

confidence: 99%

Determination of Piperacillin/Tazobactam and Ticarcillin/Clavulanate Susceptibilities in Pseudomonas aeruginosa Isolates in Hospitalised Patients by E-test Gradient Method and Comparison of Results with Disk Diffusion Tests

Direkel¹,

Uzunoğlu²,

Uzalp³

et al. 2017

Clin Microbiol

View full text Add to dashboard Cite

show abstract

“…Studies comparing these systems to reference minimum inhibitory concentration (MIC) methods found that because of the slow growth of the mucoid P. aeruginosa, very major errors (false susceptibility) were unacceptably high [13]. When the agar-based methods, disk diffusion and E-tests, were compared with reference methods, they showed excellent concordance [14]. As a result, the US Cystic Fibrosis Foundation recommended that disk diffusion or E-test be the method of choice for susceptibility testing of this organism [15].…”

Section: For Reprint Orders Please Contact: Reprints@future-drugscommentioning

confidence: 99%

“…Unfortunately, practices in the clinical microbiology laboratory have not kept pace, as evidenced by close to half of the laboratories performing P. aeruginosa susceptibility testing using methods associated with very major errors [13,16]. With increasing use of aerosolized therapy, laboratories must be able to provide susceptibility results for both tobramycin and colistin at both aerosol-and serum-achievable levels.…”

Section: For Reprint Orders Please Contact: Reprints@future-drugscommentioning

confidence: 99%

Is there value in susceptibility testing ofPseudomonas aeruginosacausing chronic infection in patients with cystic fibrosis?

Gilligan

2006

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

“…Maybe due to the lack of a strict standard policy of care for CF patients in Bulgaria, the isolates of this study, before TOBI introduction, were much more susceptible respectively: piperacillin -20.9, 29.7 and 48.2 %; ceftazidime -14.6, 39.6 and 49.9 %; tobramycin -13.1, 10.1 and 22.2 %; gentamicin -33.0, 47.0 and 52.4 %; ciprofloxacin -28.6, 29.7 and 37.4% [6][7][8]. After the initiation of inhalation regimens with TOBI the susceptibility of P. aeruginosa became much lower compared to the susceptibility reported from Spain and Germany regarding aminoglycosides, cephalosporins and fluoroquinolones (at less than 60% susceptibility for all of the three classes) and much higher regarding carbapenems (over 75% susceptibility) as in USA [5].…”

Section: Discussionmentioning

confidence: 52%

Antimicrobial susceptibility of Pseudomonas aeruginosa before and after initiation of inhaled tobramycin in Bulgaria

Petrova

Miteva

Lazova

et al. 2016

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: In aim to achieve better infection control and possible eradication of the pathogens involved in chronic infections of patients with cystic fibrosis (CF) scientists have developed a new way to administer antimicrobials -inhalation. The first and so far the only available inhalable antimicrobial in Bulgaria is inhaled tobramycin (TOBI), introduced in 2009.We aimed to evaluate the antimicrobial susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis (CF) patients before and after initiation of TOBI in the regular treatment regimen. Methodology: We have determined the minimal inhibitory concentration (MIC) of 17 antimicrobials by the E-test (LIOFILCHEM) in sputa samples of 118 CF patients for the period of 2005-2014. The results were interpreted according to the annual Clinical and Laboratory Standards Institute guidelines. Results: In the sputa of 70 patients a total of 102 P. aeruginosa isolates were found. Sixty-eight out of 102 (66.7%) were susceptible to all studied antimicrobials. We divided the isolates in two chronological groups: those collected before the introduction of TOBI as a regular treatment in 2009 and those collected after 2009. A significant reduction (p < 0,001-0,02) in susceptibility for the strains after 2009 was noted towards piperacillin (100% vs 50%), ceftazidime (100% / 77.3%), cefepime (97.9% / 68.2%), amikacin (100% / 63.6%), gentamicin (95.7% / 40.9%), tobramycin (93.6% / 59.1%) and ciprofloxacin (93.6% / 45.5%). Conclusion: The introduction of inhaled tobramycin as a regular therapy for CF patients in Bulgaria lead to a significant change in antimicrobial susceptibility of CF P. aeruginosa.

show abstract

Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients

Cited by 77 publications

References 6 publications

Determination of Piperacillin/Tazobactam and Ticarcillin/Clavulanate Susceptibilities in Pseudomonas aeruginosa Isolates in Hospitalised Patients by E-test Gradient Method and Comparison of Results with Disk Diffusion Tests

Determination of Piperacillin/Tazobactam and Ticarcillin/Clavulanate Susceptibilities in Pseudomonas aeruginosa Isolates in Hospitalised Patients by E-test Gradient Method and Comparison of Results with Disk Diffusion Tests

Is there value in susceptibility testing ofPseudomonas aeruginosacausing chronic infection in patients with cystic fibrosis?

Antimicrobial susceptibility of Pseudomonas aeruginosa before and after initiation of inhaled tobramycin in Bulgaria

Contact Info

Product

Resources

About